Private Equity Screener Refer

MARKET INSIGHTS

EventsNEWPrivate market milestones
NewsPrecize daily pulse
BlogsIn-depth articles and opinions

GUIDES

Unlisted SharesStep-by-step · KYC
BuyingStep-by-step · KYC
SellingExit in 24 - 48 hours
Pre-IPOReturns · risks · case studies
Tax GuideBudget 2026 changes

S3V Vascular Technologies – Launches Indigenous Transcatheter Aortic Valve Replacement System

Home
Unlisted share news
S3V Vascular Technologies – Launches Indigenous Transcatheter Aortic Va…

S3V Vascular Technologies – Launches Indigenous Transcatheter Aortic Valve Replacement System

12 Mar 2026

Add as preferred source

Key Takeaways

Key Takeaway:
S3V’s indigenous TAVR system could significantly lower device costs and expand access to advanced cardiac treatment in India, addressing a large unmet demand where only ~4,000 procedures are performed annually against a need of ~50,000.

Key Takeaway:
S3V’s indigenous TAVR system could significantly lower device costs and expand access to advanced cardiac treatment in India, addressing a large unmet demand where only ~4,000 procedures are performed annually against a need of ~50,000.

S3V Vascular Technologies

-0.36%

Expert Analysis

Expert Analysis:

S3V Vascular Technologies, backed by former L&T chairman A.M. Naik along with investors Utpal Sheth and Madhu Kela, has unveiled India’s first indigenous balloon-expandable Transcatheter Aortic Valve Replacement (TAVR) system.
TAVR is a minimally invasive alternative to open-heart surgery used to treat severe aortic stenosis and is widely adopted globally for elderly or high-risk patients.
The domestically engineered device aims to reduce dependence on imported heart-valve implants, which currently cost ₹13 lakh to ₹23 lakh per device, significantly limiting access to the procedure in India.
India currently performs around 4,000 TAVR procedures annually, despite an estimated clinical demand of nearly 50,000 cases, highlighting the large treatment gap the innovation seeks to address.
The system has entered preclinical testing, and subject to regulatory approvals, the company expects a commercial rollout within 12–18 months.

Publisher:Money Control